| Hypoxia regulates TSC1/2–mTOR signaling and tumor suppression through REDD1-mediated 14–3–3 shuttling MP DeYoung, P Horak, A Sofer, D Sgroi, LW Ellisen Genes & development 22 (2), 239-251, 2008 | 894 | 2008 |
| p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis JW Rocco, CO Leong, N Kuperwasser, MP DeYoung, LW Ellisen Cancer cell 9 (1), 45-56, 2006 | 507 | 2006 |
| The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers CO Leong, N Vidnovic, MP DeYoung, D Sgroi, LW Ellisen The Journal of clinical investigation 117 (5), 1370-1380, 2007 | 351 | 2007 |
| p63 and p73 in human cancer: defining the network MP Deyoung, LW Ellisen Oncogene 26 (36), 5169-5183, 2007 | 349 | 2007 |
| Negative feedback control of HIF-1 through REDD1-regulated ROS suppresses tumorigenesis P Horak, AR Crawford, DD Vadysirisack, ZM Nash, MP DeYoung, D Sgroi, ... Proceedings of the National Academy of Sciences 107 (10), 4675-4680, 2010 | 221 | 2010 |
| Cancer gene discovery using digital differential display D Scheurle, MP DeYoung, DM Binninger, H Page, M Jahanzeb, ... Cancer research 60 (15), 4037-4043, 2000 | 157 | 2000 |
| Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1 A Najafov, EM Sommer, JM Axten, MP DeYoung, DR Alessi Biochemical Journal 433 (2), 357-369, 2011 | 155 | 2011 |
| Tumor-specific p73 up-regulation mediates p63 dependence in squamous cell carcinoma MP DeYoung, CM Johannessen, CO Leong, W Faquin, JW Rocco, ... Cancer research 66 (19), 9362-9368, 2006 | 132 | 2006 |
| A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors J Mateo, G Ganji, C Lemech, HA Burris, SW Han, K Swales, S Decordova, ... Clinical Cancer Research 23 (19), 5981-5992, 2017 | 128 | 2017 |
| Identification of Down's syndrome critical locus gene SIM2-s as a drug therapy target for solid tumors MP DeYoung, M Tress, R Narayanan Proceedings of the National Academy of Sciences 100 (8), 4760-4765, 2003 | 66 | 2003 |
| Long-range inhibitor-induced conformational regulation of human IRE1α endoribonuclease activity NO Concha, A Smallwood, W Bonnette, R Totoritis, G Zhang, ... Molecular pharmacology 88 (6), 1011-1023, 2015 | 57 | 2015 |
| Inhibition of Single Minded 2 gene expression mediates tumor-selective apoptosis and differentiation in human colon cancer cells MJ Aleman, MP DeYoung, M Tress, P Keating, GW Perry, R Narayanan Proceedings of the National Academy of Sciences 102 (36), 12765-12770, 2005 | 56 | 2005 |
| Down's syndrome-associated single minded gene as a novel tumor marker. MP Deyoung, D Scheurle, H Damania, C Zylberberg, R Narayanan Anticancer research 22 (6A), 3149-3157, 2002 | 44 | 2002 |
| Down's syndrome-associated Single Minded 2 gene as a pancreatic cancer drug therapy target MP DeYoung, M Tress, R Narayanan Cancer letters 200 (1), 25-31, 2003 | 43 | 2003 |
| Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230 C Blackwell, C Sherk, M Fricko, G Ganji, M Barnette, B Hoang, J Tunstead, ... Oncotarget 7 (26), 39861, 2016 | 40 | 2016 |
| Bioinformatics-based discovery of a novel factor with apparent specificity to colon cancer. MP De Young, H Damania, D Scheurle, C Zylberberg, R Narayanan In Vivo (Athens, Greece) 16 (4), 239-248, 2002 | 38 | 2002 |
| A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma EMJ van Brummelen, E Levchenko, M Dómine, DA Fennell, HL Kindler, ... Investigational new drugs 38, 457-467, 2020 | 22 | 2020 |
| An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer D Morgensztern, N Karaseva, E Felip, I Delgado, O Burdaeva, M Dómine, ... Lung Cancer 136, 74-79, 2019 | 18 | 2019 |
| p63/p73 expression mediates cisplatin sensitivity in a subset of triple-negative primary breast cancer: Implications for a new clinical trial SJ Isakoff, C Leong, N Vidnovic, MP DeYoung, D Sgroi, PE Goss, ... Journal of Clinical Oncology 25 (18_suppl), 10522-10522, 2007 | 15 | 2007 |
| FP-1039/GSK3052230, an FGF ligand trap, enhances VEGF antagonist therapy in preclinical models of RCC and HCC DI Bellovin, S Palencia, K Hestir, E Lee, MP DeYoung, T Brennan, G Los, ... Cancer Research 74 (19_Supplement), 5449-5449, 2014 | 6 | 2014 |
